Fig. 7: The molecular mechanism by which JMJD2C affects CDDP resistance in uveal melanoma.
From: JMJD2C mediates the MDM2/p53/IL5RA axis to promote CDDP resistance in uveal melanoma
JMJD2C promotes the expression of MDM2 by removing the H3K9me3 modification of the MDM2 promoter, thus promoting the ubiquitination and degradation of p53, increasing the expression of IL5RA, and ultimately promoting CDDP resistance in uveal melanoma.
